Corient Private Wealth
RARE icon

Corient Private Wealth’s Ultragenyx Pharmaceutical RARE Stock Holding History

Corient Private Wealth’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.89M Buy
146,493
+9,949
+7% +$247K 0.01% 914
2026
Q1 		$2.86M Buy
+136,544
New +$3.07M ﹤0.01% 1076

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Corient Private Wealth's RARE Position: Q2 2026 in Review

Corient Private Wealth increased its Ultragenyx Pharmaceutical (RARE) stake by 7.3% in Q2 2026, buying an estimated $247K and bringing the position to 146,493 shares worth $4.89M. The position accounts for 0.01% of the portfolio, ranked #914.

Corient Private Wealth first reported a position in RARE in Q1 2026 and has held it in 2 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Corient Private Wealth held 146,493 shares of Ultragenyx Pharmaceutical worth $4.89M as of Q2 2026.
  • Corient Private Wealth bought 9,949 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $247K.
  • Ultragenyx Pharmaceutical made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #914 holding.
  • Corient Private Wealth first reported a position in Ultragenyx Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.